The Tesamorelin + Ipamorelin blend combines two growth-hormone-axis research peptides in a single vial: Tesamorelin, a stabilized GHRH-receptor analog, and Ipamorelin, a selective ghrelin/growth-hormone-secretagogue-receptor agonist. For research groups studying complementary secretagogue pathways, the blend enables side-by-side investigation of GHRH- and ghrelin-receptor signaling in the same preparation. Puritide Research supplies this blend as a high-purity, research-use-only material, prepared for in vitro and animal-model work and backed by third-party-verified certificates of analysis so your data rests on consistent, documented quality.
Available Sizes
- ›Tesamorelin + Ipamorelin Blend 17mg (11+6) Vial
Product Specifications
- Application
- Combined GHRH-receptor and ghrelin/GHS-receptor secretagogue research
- Appearance
- Solid, white lyophilized powder in a sealed glass vial
- Chemical Formula
- Blend, Tesamorelin C221H366N72O67S; Ipamorelin C38H49N9O5
- CAS Number
- Blend, Tesamorelin 218949-48-5; Ipamorelin 170851-70-4
- Molecular Weight
- Blend, Tesamorelin ~5135.87 g/mol; Ipamorelin ~711.86 g/mol
- Synonyms
- Tesamorelin + Ipamorelin, TH9507 + Ipamorelin blend, GHRH analog / GHS-R agonist blend
- Storage
- Store at ≤25°C, sealed, away from heat, light, and moisture. For extended storage, keep lyophilized and refrigerated or frozen.
What Is the Tesamorelin + Ipamorelin Blend?
This blend is a co-formulated research preparation containing two distinct peptides: Tesamorelin, a synthetic 44-residue analog of growth hormone-releasing hormone (GHRH) stabilized by an N-terminal trans-3-hexenoyl modification, and Ipamorelin, a pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) that acts as a selective agonist of the ghrelin / growth hormone secretagogue receptor (GHS-R). The 17 mg total reflects an 11 mg + 6 mg ratio of the two components.
In laboratory settings, the blend is studied to investigate two complementary secretagogue mechanisms in a single system: GHRH-receptor agonism (Tesamorelin) and ghrelin-receptor agonism (Ipamorelin). These pathways converge on somatotroph growth-hormone signaling through different receptors, making the blend a useful tool for studying pathway complementarity.
Present understanding derives from in vitro assays, animal models, and published research on each component. Findings should be interpreted within their experimental context and not treated as established outcomes for any use supplied by Puritide Research. The blend is supplied strictly for laboratory use and is not approved for human or veterinary application.
Blend Mechanism of Action (Research Only)
The blend is studied for its combination of two secretagogue mechanisms, GHRH-receptor agonism and ghrelin/GHS-receptor agonism, that both influence somatotroph growth-hormone signaling through distinct receptors. The mechanisms below reflect observations from biochemical assays, cell-culture studies, and animal models, and should be read strictly in a research context.
Tesamorelin: GHRH Receptor Signaling
Tesamorelin is a stabilized GHRH analog that engages the GHRH receptor (GHRHR) on pituitary somatotrophs, coupling to adenylate cyclase and cyclic-AMP-mediated cascades that regulate growth-hormone synthesis and release. Its trans-3-hexenoyl modification is associated with prolonged molecular stability in experimental systems.
Ipamorelin: Ghrelin / GHS Receptor Signaling
Ipamorelin is a selective agonist of the ghrelin / growth-hormone-secretagogue receptor (GHS-R), a distinct receptor that also promotes growth-hormone release. It is noted in the literature for its selectivity relative to earlier secretagogues.
Because the two peptides act on different receptors that converge on growth-hormone signaling, the blend is studied as a model for investigating complementary or additive secretagogue pathways, receptor cross-talk, and combined signaling dynamics under controlled conditions, serving as a research tool rather than representing a single mechanism.
Blend Research Applications
The Tesamorelin + Ipamorelin blend is investigated in preclinical studies for exploring combined secretagogue pathways within the growth-hormone axis. The observations below derive from biochemical studies, cell-based assays, and animal models, and should be interpreted within their respective settings.
Complementary Secretagogue Pharmacology
A primary application is investigating how GHRH-receptor and ghrelin-receptor agonism interact when studied together, receptor cross-talk, complementary signaling, and combined effects on growth-hormone-axis outputs in cell and animal models.
The blend is also used in comparative research contrasting single-peptide and combined-peptide preparations, examining differences in signaling profiles without establishing any therapeutic conclusion.
Growth-Hormone Axis & Metabolic Models
Researchers use the blend in animal and cell models to study growth-hormone / IGF-1 axis signaling and downstream metabolic pathways under combined secretagogue stimulation. These studies aim to improve mechanistic understanding of somatotropic signaling rather than to establish physiological or therapeutic effects.
Laboratory Safety & Handling (Research Use Only)
The Tesamorelin + Ipamorelin blend is a synthetic, lyophilized research preparation for laboratory investigation only. It should be handled by qualified personnel in controlled environments, in accordance with institutional policies, laboratory safety procedures, and applicable regulations. Because it is a two-component blend, laboratories should account for both peptides when planning analytical verification, and prioritize material integrity, traceability, and reproducibility.
Handling & Storage Guidelines
Follow institutional SOPs, chemical hygiene plans, and approved protocols; wear appropriate PPE (lab coat, gloves, eye protection); and use engineering controls where required. Record lot numbers, storage conditions, and handling activities, and retain Certificates of Analysis and batch documentation to support traceability and audit readiness.
Store material under the conditions specified in product documentation, protected from excessive heat, moisture, and direct light. Reconstituted peptide is less stable than the lyophilized form; maintain consistent conditions throughout the study period and monitor storage records as part of quality assurance.
Certificate of Analysis & Quality Assurance
Each blend batch ships with a third-party-verified Certificate of Analysis, providing transparent, research-grade quality control. Because this is a two-component preparation, the CoA documents both peptides, with purity assessment (HPLC / reverse-phase chromatography), mass-spectrometry identity confirmation, and lot number, testing date, and method documentation.
Researchers may request sample CoAs (PDF) ahead of purchase to confirm testing parameters, analytical methods, and batch consistency, and are encouraged to perform independent verification.
Research Use Only
